| AMSTAR 2 | A measurement tool to assess systematic reviews (version 2) |
| ACTH | Adrenocorticotropic hormone |
| BAI | Beck Anxiety Inventory |
| BDI | Beck Depression Inventory |
| BDNF | Brain-derived neurotrophic factor |
| CFU | Colony-forming unit |
| CI | Confidence interval |
| CRH | Corticotropin-releasing hormone |
| DSM-5 | Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition |
| GABA | Gamma-aminobutyric acid |
| GAD | Generalized anxiety disorder |
| GI Tract | Gastrointestinal tract |
| GOS | Galactooligosaccharide |
| HADS | Hospital Anxiety and Depression Scale |
| HAM-A | Hamilton Anxiety Rating Scale |
| HAM-D | Hamilton Depression Rating Scale |
| HPA Axis | Hypothalamic |
| Pituitary | Adrenal axis |
| HDAC | Histone deacetylase |
| IBS | Irritable bowel syndrome |
| IL-6 | Interleukin-6 |
| IL-10 | Interleukin-10 |
| KYN Pathway | Kynurenine pathway |
| MeSH | Medical subject headings |
| NE | Norepinephrine |
| PRISMA | Preferred Reporting Items for Systematic Reviews and Meta-Analyses |
| PROSPERO | International Prospective Register of Systematic Reviews |
| QOL | Quality of life |
| RCT | Randomized controlled trial |
| SCFAs | Short-chain fatty acids |
| SCID | Structured Clinical Interview for DSM Disorders |
| SMD | Standardized mean difference |
| SNRI | Serotonin–norepinephrine reuptake inhibitor |
| SSRI | Selective serotonin reuptake inhibitor |
| STAI | State-Trait Anxiety Inventory |
| TNF-α | Tumor necrosis factor–alpha |
| WHOQOL-BREF | World Health Organization Quality of Life–Brief Version |